0      0

JL1116ES - JL1116ES: IMpower010: overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC

‐ Oct 30, 2023 9:00am

Full author listing 

Enriqueta Felip, MD1 Nasser Altorki, MD2 Eric Vallieres, MD3 Ihor O. Vynnychenko, MD4 Andrey Akopov, MD5 Alex Martinez-Marti, MD1 Antonio Chella, MD6 Igor Bondarenko, MD 7 Shunichi Sugawara, MD, PhD 8 Yun Fan, MD9 Hirotsugu Kenmotsu, MD10 Yuh-Min Chen, MD11 Yu Deng, PhD12 Meilin Huang, PhD12 Virginia McNally, PhD13 Elizabeth Bennett, PhD12 Barbara J. Gitlitz, MD12 Caicun Zhou, MD14 Heather A. Wakelee, MD15

1Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 2New York-Presbyterian Hospital, Weill Cornell Medicine, New York,

NY, USA; 3Swedish Cancer Institute, Seattle, WA, USA; 4Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, Sumy State University, Sumy, Ukraine; 5Pavlov State Medical University, Saint Petersburg, Russia; 6Pneumology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; 7Dnipro State Medical University, Dnipro, Ukraine; 8Sendai Kousei Hospital, Miyagi, Japan; 9Zhejiang Cancer Hospital, Hanzhou, China; 10Shizuoka Cancer Center, Shizuoka, Japan; 11Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Taipei, Taiwan; 12Genentech Inc, South San Francisco, CA, USA; 13Roche Products Ltd, Welwyn Garden City, United Kingdom; 14Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China; 15Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA


You must be logged in and own this session in order to post comments.